A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Zavegepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company; Pfizer
- 01 May 2024 Status changed from active, no longer recruiting to discontinued. (Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.)
- 20 Mar 2024 Planned End Date changed from 12 Mar 2024 to 20 Mar 2024.
- 20 Mar 2024 Planned primary completion date changed from 12 Mar 2024 to 20 Mar 2024.